Mammary Cell News Volume 12.09 | Mar 12 2020

TOP STORY

Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-Repressor in Breast Cancer

Scientists report that neurofibromin, a tumor suppressor and Ras-GTPase-activating protein, was also an estrogen receptor-α transcriptional co-repressor through leucine/isoleucine-rich motifs that were functionally independent of GAP activity. [Cancer Cell] Abstract | Graphical Abstract

(Ranked by impact factor of the journal)

Transcriptional Diversity and Bioenergetic Shift in Human Breast Cancer Metastasis Revealed by Single-Cell RNA Sequencing

Researchers found that both primary tumors and micrometastases displayed transcriptional heterogeneity but micrometastases harbored a distinct transcriptome program conserved across patient-derived-xenograft models that was highly predictive of poor survival of patients. [Nat Cell Biol] Abstract

Targeting MYCN-Expressing Triple-Negative Breast Cancer with BET and MEK Inhibitors

The authors report that MYCN, an oncogene typically overexpressed in tumors of the nervous system or with neuroendocrine features, was heterogeneously expressed within a substantial fraction of primary and recurrent triple-negative breast cancer (TNBC) and was expressed in an even higher fraction of TNBCs that did not display a pathological complete response after neoadjuvant chemotherapy. [Sci Transl Med] Full Article

Tumor Cell-Organized Fibronectin Maintenance of a Dormant Breast Cancer Population

To understand the role of the extracellular matrix (ECM) in regulating tumor dormancy, scientists created an in vitro cell culture system with carefully controlled ECM substrates to observe entrance into and exit from dormancy with live imaging. [Sci Adv] Full Article

AhR Ligands Reactivate LINE-1 Retrotransposon in Triple-Negative Breast Cancer Cells MDA-MB-231 and Non-Tumorigenic Mammary Epithelial Cells NMuMG

Hexachlorobenzene and chlorpyrifos exposure modified long interspersed nuclear element-1 (LINE-1) methylation levels and induced LINE-1 reactivation, suggesting that epigenetic mechanisms could contribute to pesticide-induced breast cancer progression. [Biochem Pharmacol] Abstract | Graphical Abstract

Evaluation of Lumican Effects on Morphology of Invading Breast Cancer Cells, Expression of Integrins and Downstream Signaling

Investigators analyzed the effects of lumican in three breast cancer cell lines: the highly metastatic estrogen receptor (ER)β-positive MDA-MB-231, cells with the respective ERβ suppressed and lowly invasive ERα-positive MCF-7/c breast cancer cells. [FEBS J] Abstract

A Novel Hotspot Specific Isothermal Amplification Method for Detection of the Common PIK3CA p.H1047R Breast Cancer Mutation

Scientists report a novel strategy with proof-of-concept data that supported the usage of loop-mediated isothermal amplification to detect PIK3CA c.3140-A > G (H1047R), a prevalent breast cancer (BC) missense mutation that was attributed to BC tumor growth. [Sci Rep] Full Article

miR-485-5p Inhibits the Progression of Breast Cancer Cells by Negatively Regulating MUC1

Overexpression of miR-485-5p inhibited cell viability and invasion and migration of breast cancer cell line MCF-7 and promoted apoptosis. [Breast Cancer] Abstract

Novel Aptamers Selected on Living Cells for Specific Recognition of Triple-Negative Breast Cancer

The authors identified a panel of 2′-fluoropyrimidine-RNA aptamers binding to triple-negative breast cancer cells and their cisplatin- and doxorubicin-resistant derivatives at low nanomolar affinity. [iScience] Abstract | Graphical Abstract

Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News.

Clinical Development of Immunotherapies for HER2⁺ Breast Cancer: A Review of HER2-Directed Monoclonal Antibodies and Beyond

Scientists summarize advances in the understanding of immune system interactions, examine clinical developments, and suggest rationales for future investigation of immunotherapies for human epidermal growth factor receptor 2-positive (HER2⁺) breast cancer. [npj Breast Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Immutep Receives Second IND Approval for Efti from US FDA

Immutep Limited announced the approval of its Investigational New Drug (IND) application by the FDA for eftilagimod alpha (efti). The FDA approval of the IND allows Immutep to initiate its planned AIPAC-002 Phase I clinical study in metastatic breast cancer patients. [Immutep Limited] Press Release

At the Recommendation of the FDA, CytoDyn Will Request a Preliminary Breakthrough Therapy Designation Meeting

CytoDyn Inc. announced that the FDA recommended that the company request a preliminary breakthrough therapy designation meeting. Meanwhile, the company continues reporting very positive data for its metastatic triple-negative breast cancer and metastatic breast cancer patients. [CytoDyn Inc.] Press Release

Institute for Women’s and Children’s Health Launched at The Lundquist Institute

Focused on excellence in clinical and translational research related to women’s care, pediatric health and the impact of pregnancy on child and adult health and disease, the Institute for Women’s and Children’s Health brings together a multidisciplinary, trans-sectorial group of investigators with expertise ranging from public health to clinical medicine, as well as newer fields like translational science. [The Lundquist Institute] Press Release

Universities Are Forging Ties with the FBI as US Cracks Down on Foreign Influence

US universities are forging closer ties with FBI agents, encouraging scientists to disclose foreign sources of research funding, and tightening restrictions on researchers’ travel. [Nature News] Editorial

Hundreds of Scientists Have Peer-Reviewed for Predatory Journals

Hundreds of scientists who post their peer-review activity on the website Publons say they’ve reviewed papers for journals termed ‘predatory’, an analysis has found. The site hosts at least 6,000 records of reviews for more than 1,000 predatory journals. [Nature News] Editorial

NEW Advances in Breast Cancer Research
October 9-12, 2020
San Diego, California, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Training Fellow – Endocrine Control Mechanisms (Institute of Cancer Research)

Postdoctoral Investigator – Breast Cancer Cell Biology (Florida Atlantic University)

Research Assistant – 3D Models of Breast Cancer (University of Cambridge)

Postdoctoral Associate – Oncology (University of Miami Health System)

Postdoctoral Research Position – Breast Cancer Research (The University of Texas)

Postdoctoral Position – Breast Cancer Metastasis (University of Kentucky)

Research Fellow – Breast Cancer (Dana-Farber Cancer Institute)

Postdoctoral Fellow – Breast Tumorigenesis (University of Cincinnati)

Postdoctoral Position – DNA Nanotechonology in Cancer (University of Duisburg-Essen)

Postdoctoral Fellow – Clonal Evolution of Cancer (Moffitt Cancer Center & Research Institute)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.